Skin Cancer And Radiotherapy Review

Dr. Jordan Stosky, MD, FRCPC, DABR

Radiation Oncology Review Course

January 21, 2024

Disclosures

- No outside funding to disclose
- Parts of this presentation were prepared with a young ptyrodactyl snuggle muffin at home

We have 1 hour

- What this is:
  - A basic science and anatomy refresher as it pertains to skin cancer and radiotherapy
  - An overview of *some* of the literature supporting and guiding treatment decisions in the use of radiotherapy in skin cancers

- What this is not:
  - A complete review of systemic agents and their use in skin cancers
    - Eg immunotherapy, targeted therapies
  - An exhaustive treatment planning compendium

We have 1 hour

- What this is:
  - ~~A basic science and~~ anatomy refresher as it pertains to skin cancer and radiotherapy
  - An overview of *some* of the literature supporting and guiding treatment decisions in the use of radiotherapy in skin cancers
- What this is not:
  - A complete review of systemic agents and their use in skin cancers
    - Eg immunotherapy, targeted therapies
  - An exhaustive treatment planning compendium

We have 1 hour

- What this is:
  - ~~A basic science and~~ anatomy refresher as it pertains to skin cancer and radiotherapy
  - An overview of *some* of the literature supporting and guiding treatment decisions in the use of radiotherapy in skin cancers
- What this is not:
  - A complete review of systemic agents and their use in skin cancers
    - Eg immunotherapy, targeted therapies
  - ~~An exhaustive treatment planning compendium~~

We have 1 hour

- What this is:
  - ~~A basic science and~~ anatomy refresher as it pertains to skin cancer and radiotherapy
  - An overview of *some* of the literature supporting and guiding treatment decisions in the use of radiotherapy in skin cancers
  - Review high yield treatment planning concepts
- What this is not:
  - A complete review of systemic agents and their use in skin cancers
    - Eg immunotherapy, targeted therapies
  - ~~An exhaustive treatment planning compendium~~

Objectives

01

Review Melanoma and Radiotherapy

02

Review Merkel Cell Carcinoma and Radiotherapy

03

Review BCC and SCC and Radiotherapy

04

Review Treatment Planning Concepts

05

Anatomy Refresher

Melanoma Risk factors

- UVB
  - Greatest increase in RR in people who experience blistering sunburns
- Fair complexion
- Numerous benign or larger atypical nevi (>5mm)
  - 15% of melanomas are from melanocytic nevi
  - <10% are from non cutaneous sites. Commonly:
    - Mucosal
    - Uveal
    - Gyne areas
- Personal hx (HR 900)
- Family hx

Don’t forget your ABCDEs



Melanoma Genetics

- 10% familial with mutations in:
  - CDKN2A
  - CDK4
  - XP
  - BRCA2
- Familial atypical multiple mole-melanoma syndrome (FAMMM)
- CDKN2A mutation in >70% of lesions
- BRAF mutations
  - Younger, male patients
  - Tends to be more aggressive
  - 40-60% in advance disease

Normal Skin histology



Clark's levels

1. Confined to epidermis (in situ)
2. Invasion into papillary dermis
3. Invasion to junction of papillary and reticular dermis
4. Invasion into reticular dermis
5. Invasion into subcutaneous fat

Staging and Prognosis

N Category	Number of tumor-involved regional lymph nodes	Presence of in-transit, satellite and/or microsatellite metastases	T Category								
			T0	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
			No evidence of primary tumor	<0.8 mm without ulceration	<0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration	>1.0-2.0 mm without ulceration	>1.0-2.0 mm with ulceration	>2.0-4.0 mm without ulceration	>2.0-4.0 mm with ulceration	>4.0 mm without ulceration	>4.0 mm with ulceration
N0	No regional metastases detected	No	-	IA	IA	IB	IIA	IIA	IIB	IIB	IIC
N1a	1 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC	IIIC	IIIC
N1b	1 clinically detected	No	IIIB	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N1c	No regional lymph node disease	Yes	IIIB	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N2a	2 or 3 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC	IIIC	IIIC
N2b	2 or 3, at least 1 of which was clinically detected	No	IIIC	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N2c	1 clinically occult or clinically detected	Yes	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC
N3a	≥4 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID
N3b	≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes	No	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID
N3c	≥2 clinically occult or clinically detected and/or presence of any number of matted nodes	Yes	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID

T0 — no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma); **Tis** — melanoma in situ;
Tx — thickness cannot be assessed. (Tis and Tx are not included in the table but are part of the staging system.)
Nx — Regional nodes not assessed (e.g., SLN biopsy not performed, regional nodes previously removed for another reason).
Exception: pathological N category is not required for T1 melanomas, use clinical N information. (If an SLNB was performed, the results can and *should* be used for pathological evaluation.)

T Category								
T0	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
No evidence of primary tumor	<0.8 mm without ulceration	<0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration	>1.0-2.0 mm without ulceration	>1.0-2.0 mm with ulceration	>2.0-4.0 mm without ulceration	>2.0-4.0 mm with ulceration	>4.0 mm without ulceration	>4.0 mm with ulceration



N Category	Number of tumor-involved regional lymph nodes	Presence of in-transit, satellite and/or microsatellite metastases
N0	No regional metastases detected	No
N1a	1 clinically occult (i.e., detected by SLN biopsy)	No
N1b	1 clinically detected	No
N1c	No regional lymph node disease	Yes
N2a	2 or 3 clinically occult (i.e., detected by SLN biopsy)	No
N2b	2 or 3, at least 1 of which was clinically detected	No
N2c	1 clinically occult or clinically detected	Yes
N3a	≥4 clinically occult (i.e., detected by SLN biopsy)	No
N3b	≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes	No
N3c	≥2 clinically occult or clinically detected and/or presence of any number of matted nodes	Yes




Melanoma-Specific Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.0
1
2
3
4
5
6
7
8
9
10
Years Since Diagnosis
N 5-YR 10-YR
IA 5225 99% 98%
IB 5749 97% 94%
IIA 2338 94% 88%
IIB 1688 87% 82%
IIC 691 82% 75%


Melanoma-Specific Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
2
4
6
8
10
Years Since Diagnosis
N 5-YR 10-YR
IIIA 1006 93% 88%
IIIB 1170 83% 77%
IIIC 2201 69% 60%
IIID 205 32% 24%

M Staging

- What is needed for melanoma M staging?
  - Anatomy involved
  - Don’t forget LDH

M Category	M Criteria	
	Anatomic site	LDH level
M0	No evidence of distant metastasis	Not applicable
M1	Evidence of distant metastasis	See below
M1a	Distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node	Not recorded or unspecified
M1a(0)		Not elevated
M1a(1)		Elevated
M1b	Distant metastasis to lung with or without M1a sites of disease	Not recorded or unspecified
M1b(0)		Not elevated
M1b(1)		Elevated
M1c	Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease	Not recorded or unspecified
M1c(0)		Not elevated
M1c(1)		Elevated
M1d	Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease	Not recorded or unspecified
M1d(0)		Normal
M1d(1)		Elevated

Suffixes for M category: (0) LDH not elevated, (1) LDH elevated.
No suffix is used if LDH is not recorded or is unspecified.

Pathological subtypes

- Superficial spreading (70%), worst prognosis
- Lentigo maligna (insitu – freckle), lentigo maligna melanoma (invasive)
  - 10% LN positive, 5y OS 85% WLE alone
- Acral lentiginous
  - Increased in dark skinned, palms, soles
- Nodular (no radial growth)
- Desmoplastic
  - Older, more PNI, increased LR, decreased LN
- Mucosal melanoma (1%)

Presentation

- 5% with DM at diagnosis
  - 33% of these with unknown primary
- 85% with localized disease
- 10% present with regional disease

Workup

- Stage I-II
  - Imaging only to evaluate specific symptoms
- Stage III
  - SLN+ consider baseline imaging
  - cN+ or intransit, local and distant imaging
- SLNB if:
  - >0.75mm
  - Consider if ulceration, LVSI, and/or mitotic rate >=1mm2
- Clinical LN exam has 20% discordance

NCCN Margins – 3.2023

PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA

Tumor Thickness	Recommended Clinical Margins[b]
In situ[a]	0.5–1.0 cm
≤1.0 mm	1.0 cm (category 1)
>1.0–2 mm	1–2 cm (category 1)
>2.0–4 mm	2.0 cm (category 1)
>4 mm	2.0 cm (category 1)

- Margins may be modified to accommodate individual anatomic or functional considerations.
- Consider histologic margin assessment prior to reconstruction and closure.

Treatment of locally advanced melanoma

- Care pathways complex, evolving as evidence for systemic therapy advances
- High-dose interferon-α x1 year after resection for high risk melanoma
  - Stages IIB, IIC, III
  - Many trials – ECOG 1684/1690/1694
- Adjuvant ipilumumab in stage III disease (EORTC 18071)
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma – SWOG S1801

Post-hoc meta-analysis of EORTC 18952 18991, Eggermont et al, 2012



Stage IIb/III-N1: HR 0·58 (99% CI 0·40–0 · 86), p=0·0003.
Stage III-N2: HR 0·89 (99% CI 0·62 to –1· 28), p=0·41.

EORTC 18071 – Long term followup, Eggermont et al, 2019



SWOG S1801 – Patel, NEJM 2023
Neoadjuvant vs Adjuvant IO



Adjuvant RT

- **TROG 02.01** (Burmeister Lancet ‘12, Henderson ‘15)
  - Palpable LND +- ISRT 48 Gy / 20 fr (margin+ 51 Gy/21)
  - SLNB not allowed
  - Nonmetastatic palpable LN at dx or at LN relapse
  - 1 parotid, 2 neck, 2 axilla, 3 groin, >=3cm neck, >=4cm axillary/inguinal
    - **“1,22,33,4”**
  - <5% of patients got adjuvant interferon

TROG 02.01



Figure 2: **Cumulative incidence curves of lymph-node field relapse as a site of first relapse (competing risks: other relapse and death)**



Figure 3: **Overall survival of eligible patients**

Adjuvant RT indications

- Burmeister criteria
- Usually in nodal recurrences, given no survival differences
- No randomized controlled trial of adjuvant immunotherapy vs RT
  - Or RT vs no RT in immunotherapy era
- Also consider ECE, >4mm esp if ulcerated or with satellitosis, and SLNB+ without completion dissection
- Discuss with your medical oncologist, melanoma surgeon

Hypofractionation – 30 Gy / 5 2-3x/week

- Several phase II studies, retrospective
  - MDACC – Ang IJROBP ‘94, Ballo Cancer ’06
- UF 60Gy /30 vs 30 Gy/ 5
  - Chang IJROBP ‘09

- Bottom line
  - Probably equally as efficacious as moderate hypo or standard frac
  - Late toxicity a bit worse, cosmesis worse

Definitive RT

- a/b ratio ~ 0.4-2.5
- Retrospective data showed increasing efficacy with fraction size
  - Lead to RTOG 8305 – definitive palliation of 32 Gy/4 fr vs 50 Gy / 20
    - No difference in LR< 32 Gy toxic with G4 toxicity
    - CR ~ 25%
- 50-55Gy/20 daily
- 42 Gy – 54 Gy / 6 biweekly

NCCN - Metastatic Disease



Metastatic disease

- Nivolumab – Anti-PD-1
- Pembrolizumab – Anti-PD-1
- Ipilimumab – CTLA4 antibody
- **Nivolumab + Ipilimumab**
- Vemurafenib, Dabrafenib (BRAF inhibitors, V600 mutation)
- IL-2
- Imatinib (C-kit)

PD-1 vs PD-L1 and Tumor Microenvironment

PD-1	PDL-1
Expressed on T-Cells	Expressed on tumor cells, antigen presenting cells
Anti-PD-1	**Anti-PDL-1**
Pembrolizumab Nivolumab Cemiplimab	Atezolizumab Avelumab Durvolumab



Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019


enhanced immune function
plus IT
DCs
Tumour
I WANT TO BELIEVE

Oligometastatic melanoma – to SBRT or not to SBRT?

- Not yet standard of care
- SABR-COMET is intriguing
- No melanoma-only randomized data, however guidelines are now adopting this a a practice option
- Best done with multidisciplinary input (and even better, if on a clinical trial)

rapid communications

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, MD, PhD[1]; Robert Olson, MD, MSc[2]; Stephen Harrow, MBChB, PhD[3]; Stewart Gaede, PhD[1]; Alexander V. Louie, MD, PhD[4]; Cornelis Haasbeek, MD, PhD[5]; Liam Mulroy, MD[6]; Michael Lock, MD[1]; George B. Rodrigues, MD, PhD[1]; Brian P. Yaremko, MD, PEng[1]; Devin Schellenberg, MD[7]; Belal Ahmad, MD[1]; Sashendra Senthi, MD, PhD[8]; Anand Swaminath, MD[9]; Neil Kopek, MD[10]; Mitchell Liu, MD[11]; Karen Moore, MSc[3]; Suzanne Currie, MSc[3]; Roel Schlijper, MD[2]; Glenn S. Bauman, MD[1]; Joanna Laba, MD[1]; X. Melody Qu, MD, MPH[1]; Andrew Warner, MSc[1]; and Suresh Senan, MBBS, PhD[5]



CHEERS Trial – Spaas et al, JAMA Onc 2023

JAMA Oncology | Original Investigation

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

The CHEERS Phase 2 Randomized Clinical Trial

Mathieu Spaas, MD; Nora Sundahl, PhD; Vibeke Kruse, PhD; Sylvie Rottey, PhD; Daan De Maeseneer, MD; Fréderic Duprez, PhD; Yolande Lievens, PhD; Veerle Surmont, PhD; Lieve Brochez, PhD; Dries Reynders, MSc; Willeke Danckaert, MSc; Els Goetghebeur, PhD; Robbe Van den Begin, PhD; Dirk Van Gestel, PhD; Vincent Renard, MD; Piet Dirix, PhD; Piet Ost, PhD

- Randomized patients with metastatic melanoma to anti-PD-1/PD-L1 monotherapy to +/- 8 Gy x 3 to up to 3 extra-cranial lesions

CHEERS Trial – Spaas et al, JAMA Onc 2023

A Progression-free survival



No. at risk									
Control arm	51	20	12	10	7	4	2	2	1
Experimental arm	45	18	12	9	9	8	7	6	2
Cumulative No. of censoring									
Control arm	0	2	3	4	6	7	9	9	10
Experimental arm	0	2	2	2	2	2	3	4	8

B Overall survival



No. at risk											
Control arm	51	36	29	19	12	9	5	3	1	0	0
Experimental arm	45	33	30	20	18	15	11	10	5	2	0
Cumulative No. of censoring											
Control arm	0	0	1	4	10	13	16	18	20	21	21
Experimental arm	0	0	0	1	2	3	7	8	13	16	18

CHEERS Trial – Spaas et al, JAMA Onc 2023

- Small randomized Phase II (but so was SABR-COMET)
- Three quarters of patients had >3 extra-cranial lesions
  - So very small amount of patients with ‘oligometastatic’ disease
- Metastatic systemic therapy was monotherapy and not combination anti PD-1/CTLA-4
- 8 Gy x 3 BED is ‘low’

Oligometastatic Melanoma

National Comprehensive Cancer Network®

NCCN Guidelines Version 3.2023
Melanoma: Cutaneous

NCCN Guidelines Index
Table of Contents
Discussion



See footnotes on ME-16A

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

Annals of Oncology 30: 1884–1901, 2019
doi:10.1093/annonc/mdz411
Published online 30 September 2019

SPECIAL ARTICLE

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

O. Michielin[1], A. C. J. van Akkooi[2], P. A. Ascierto[3], R. Dummer[4] & U. Keilholz[5], on behalf of the ESMO Guidelines Committee*

[1]Department of Oncology, University Hospital Lausanne, Lausanne, Switzerland; [2]Department of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; [3]Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy; [4]Department of Dermatology, Skin Cancer Centre, University Hospital Zürich, Zürich, Switzerland; [5]Charité Comprehensive Cancer Centre, Charité-Universitätsmedizin Berlin, Berlin, Germany

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, CH-6900 Lugano, Switzerland; E-mail: clinicalguidelines@esmo.org

†Approved by the ESMO Guidelines Committee: February 2002, last update September 2019.

This publication supersedes the previously published version—Ann Oncol 2015; 26 (Suppl 5): v126-v132.

Key words: cutaneous melanoma, clinical practice guidelines, diagnosis, treatment, follow-up

Management of advanced/metastatic disease

Surgical or ablative treatment of resectable stage IV

Some stage IV patients present with a resectable, oligometastatic disease. Although the value of complete surgery or ablative radiosurgery in such a clinical setting has not been validated in phase III prospective studies, data from phase II are available [73]. Surgical removal or stereotactic irradiation of locoregional recurrence or single distant metastasis should be considered in fit patients, as a therapeutic option, offering potential for long-term disease control [III, C]. Surgery remains an option for selected patients, preferentially combined with adjuvant systemic therapies [see section on adjuvant systemic therapy].

ESMO Melanoma CPG

Melanoma Summary

- Fewer indications for adjuvant radiotherapy in immunotherapy era
  - Still consider in high risk patients
- Probably an increase role for SBRT for those with ‘oligometastatic disease’
- Neoadjuvant immunotherapy in locally advanced melanoma is coming

Merkel Cell Carcinoma

Merkel Cell Carcinoma - Rare

- Rare - ~0.6/100 000 people/ year
- Canada – estimated 290 diagnoses/year

MCC – Population Trends

ORIGINAL ARTICLES

Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics

Kelly G. Paulson, MD, PhD,[a,b] Song Youn Park, MD,[b] Natalie A. Vandeven, PhD,[b] Kristina Lachance, MS,[b] Hannah Thomas, BS,[b] Aude G. Chapuis, MD,[a,b] Kelly L. Harms, MD, PhD,[c] John A. Thompson, MD,[a,b] Shailender Bhatia, MD,[a,b] Andreas Stang, MD, MPH,[d] and Paul Nghiem, MD, PhD[a,b]
Seattle, Washington; Ann Arbor, Michigan; and Essen, Germany

See related articles on pages 433 and 445

Projected 15% Relative increase in absolute incidence from 2020 - 2025





Merkel Cell Carcinoma Genetics

- Merkel cell polyomavirus (MCV) detected in >80%
- MCV viral proteins bind to RB, interfering with TP53
- MCV neg – UV induced mutational inactivation of p53 and Tb, more mutations (prognosis ?worse)
- CK20- associated with MCV

Merkel Cell Histology

- Cell of origin thought to be epidermal or dermal cell, rather than differentiated Merkel cell
  - ie not a tactile neuroendocrine epithelial cell (aka touch cell)
- One of those small round blue cell tumors



MCC - Immunohistochemistry

European Journal of Cancer (2015) 51, 2396–2403

Available at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

Celeste Lebbe [a,*], Jürgen C. Becker [b], Jean-Jacques Grob [c], Josep Malvehy [d], Veronique del Marmol [e], Hubert Pehamberger [f], Ketty Peris [g], Philippe Saiag [h], Mark R. Middleton [i], Lars Bastholt [j], Alessandro Testori [k], Alexander Stratigos [l], Claus Garbe [m], on behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)

Table 1
Immunohistochemistry, adapted from Becker et al. [1].

	Merkel cell carcinoma (MCC)	Lymphoma	Melanoma	SCLC*
CK 20	+	−	−	−
Neuron-specific-enolase	+	−	−	+/−
Chromogranin A (CgA)	+/−	−	−	+/−
Huntingtin interacting protein 1 (HIP1)	+	+/−	−	−
Vimentin	−	+	+	−
Melan-A/MART-1	−	−	+	−
Leucocyte common antigen (LCA)	−	+	−	−
Thyroid transcription factor-1 (TTF-1)	−	−	−	+

* SCLC small cell lung cancer.

Merkel Cell Presentation

- Rapidly enlarging, painless, red denuded nodule
- 65% local dz
- 25% regional
- 10% DM
- 20% have occult LN involvement, even if <2cm primary
- Ultimately DM in 50-60%
- Need PET staging and followup



TABLE 19.2: AJCC 8th ed. (2017) Staging for Merkel Cell Carcinoma[6]

T/M \ N		cN0	cN1	pN1a(sn)	pN1a	pN1b	c/pN2	c/pN3
T1	• ≤2 cm	**I**	**IIIA**			**IIIB**		
T2	• 2.1–5 cm	**IIA**						
T3	• >5 cm							
T4	• Invasion[1]	**IIB**						
M1a	• Distant skin • Subcutaneous tissue • Distant LN	**IV**						
M1b	• Lung							
M1c	• Any other visceral sites							

Major changes in the AJCC 8th Edition include delineation between clinical & pathologic N categories, new N2-N3 categories and updates to the prognostic staging groups.

Notes: Invasion[1] = Invasion into fascia, cartilage, bone, or muscle.

cN1, metastasis in regional LN(s); pN1a(sn), clinically occult regional LN identified by sentinel lymph node biopsy only; pN1a, clinically occult regional LN following lymph node dissection; pN1b, clinically and/or radiologically detected regional LN with microscopic confirmation; c/pN2, in-transit metastasis (discontinuous from primary tumor, located between primary tumor and draining lymph node basin), without LN metastasis; c/pN3, in-transit metastasis with LN metastasis.

Treatment

- WLE with 1-2cm margin
  - cN+ -> FNA
  - cN(-) -> SLNB
- LC 40-50% with Sx alone
  - 80% with adj RT



Fig. 2. Forrest plot for overall survival analysis.

Risk factors for recurrence

- Thickness/DOI
- LVSI
- Infiltrative growth
- SLN status

Adjuvant RT

- Recurrences recur early
  - Treat early, ideally w/in 4-6 weeks
- Could consider observation:
  - <1-2cm, widely excised, no LVI, not immunosuppressed

Stage I MCC - Obs vs RT

Annals of Oncology

Annals of Oncology 23: 1074–1080, 2012
doi:10.1093/annonc/mdr318
Published online 12 July 2011

Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study

T. Jouary[1]*, C. Leyral[1], B. Dreno[2], A. Doussau[3], B. Sassolas[4], M. Beylot-Barry[5], C. Renaud-Vilmer[6], B. Guillot[7], P. Bernard[8], C. Lok[9], C. Bedane[10], F. Cambazard[11], L. Misery[12], E. Estève[13], S. Dalac[14], L. Machet[15], F. Grange[16], P. Young[17], F. Granel-Brocard[18], F. Truchetet[19], B. Vergier[20], M. M. Delaunay[1] & J. J. Grob[21] for the Groupe de Cancérologie Cutanée of the Société Française de Dermatologie

[1]*Skin Cancer Unit, Dermatology Department, Hôpital Saint André, Bordeaux;* [2]*Department of Dermatology, Hôpital Hôtel Dieu, Nantes;* [3]*Bordeaux School of Public Health, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux 2, Bordeaux;* [4]*Department of Dermatology, Hôpital Morvan, Brest;* [5]*Department of Dermatology, Hôpital du Haut-Lévêque, Bordeaux Pessac;* [6]*Department of Dermatology, Hôpitaux Saint Louis et Saint Cloud, Paris;* [7]*Department of Dermatology, Hôpital Saint Eloi, Montpellier;* [8]*Department of Dermatology, Hôpital Robert Debré, Reims;* [9]*Department of Dermatology, Hôpital Sud, Amiens;* [10]*Department of Dermatology, Hôpital Dupuytren, Limoge;* [11]*Department of Dermatology, Hôpital Nord, Saint Etienne;* [12]*Department of Dermatology, Hôpital Edouard Herriot, Lyon;* [13]*Department of Dermatology, Hôpital Porte Madeleine, Orléans;* [14]*Department of Dermatology, Hôpital du Bocage, Dijon;* [15]*Department of Dermatology, Hôpital Trousseau, Tours;* [16]*Department of Dermatology, Hôpital Pasteur, Colmar;* [17]*Department of Dermatology, Hôpital Charles Nicolle, Rouen;* [18]*Department of Dermatology, Hôpital Fournier, Nancy;* [19]*Department of Dermatology, Hôpital Beauregard, Thionville;* [20]*Department of Pathology, Hôpital du Haut-Lévêque, Bordeaux Pessac;* [21]*Department of Dermatology, Hôpital Sainte-Marguerite, Marseille, France*

Received 11 February 2011; revised 10 May 2011; accepted 12 May 2011



Stage I MCC – Obs vs RT

- ~100% regional control
- RT is effective – radiosensitive tumor



Figure 3. Regional recurrence probability according to the randomization group (group A: $n = 39$ patients; group B: $n = 44$ patients), $P = 0.007$. The group A curve intermingles with the abscises line as no patient experienced regional recurrence in this group.

Prognosis – Song, ASO 2020

- 50% stage I, 36% stage III
- MFU 3y
- Regional or DM in ~60%



FIG. 4 Kaplan–Meier estimates of Merkel cell-specific survival

Treatment planning

- Cutaneous Oncology Group of French Society of Dermatology Guidelines (Boccara Eur J Derm 2012)
  - 50 Gy + 3cm margins +10 Gy boost to tumor bed
- CTV at least >=2cm in H&N
- CTV = 3-5cm elsewhere

- R0: 50-56 Gy
- R1: 56- 60 Gy
- R2 or gross nodes 60-66 Gy
- cN0 without nodal evaluation
  - 45 – 50 Gy
- Coverage of LNs for SLNB(-) or LND(-) is controversial

Hypofractionation?

Radiotherapy and Oncology 173 (2022) 32–40

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

Original Article

Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma

Kevin X. Liu [a], Michael G. Milligan [a], Jonathan D. Schoenfeld [a,b], Roy B. Tishler [a,b], Andrea K. Ng [a], Phillip M. Devlin [a], Elliott Fite [a], Guilherme Rabinowits [c], Glenn J. Hanna [b,d], Ann W. Silk [b,d], Charles H. Yoon [b,e], Manisha Thakuria [b,f], Danielle N. Margalit [a,b,*]

[a] *Department of Radiation Oncology, Brigham & Women's Hospital/Dana-Farber Cancer Institute;* [b] *Merkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham & Women's Cancer Center, Boston;* [c] *Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, United States;* [d] *Department of Medical Oncology, Dana-Farber Cancer Institute;* [e] *Division of Surgical Oncology, Department of Surgery, Dana-Farber/Brigham and Women's Cancer Center; and* [f] *Department of Dermatology, Dana-Farber Cancer Institute, Boston, United States*





MCC – Dose and Fractionation – RCR 4th edition



Recommendations

Primary MCC and/or draining lymph node regions:

Definitive treatment:

- 60–66 Gy in 30–33 fractions over 6–6.5 weeks (Grade C)
- 50–55 Gy in 20–25 fractions over 4–5 weeks (Grade C)
- 45–50 Gy in 20 fractions over 4 weeks (Grade D)
- 30–35 Gy in 10 fractions over 2 weeks (Grade D)

Adjuvant treatment:

- 50–60 Gy in 25–30 fractions over 5–6 weeks (Grade C)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-Based Medicine.[14]

MCC – NCCN Part 1

National Comprehensive Cancer Network®

NCCN Guidelines Version 1.2024
Merkel Cell Carcinoma

NCCN Guidelines Index
Table of Contents
Discussion

PRINCIPLES OF RADIATION THERAPY

General Principles[1,2]

- Expeditious initiation of adjuvant RT after surgery is preferred as soon as wound healing permits, as delay has been associated with worse outcomes.
- There is limited evidence supporting dosing recommendations for MCC. Dose ranges provided are based on clinical practice at NCCN Member Institutions and clinical evidence from studies of other types of skin cancer.

General Treatment Information–Primary MCC Tumor Site

- Treatment Information
  - Bolus is used to achieve adequate skin dose. Wide margins (5 cm) should be used around the primary site, when clinically feasible with consideration given to anatomic constraints. If electron beam is used, an energy and prescription isodose should be chosen that will deliver adequate dose to the lateral and deep margins.
- General Dosing Prescription
  - All doses are at 2 Gy/day standard fractionation.
  - In the palliative setting, a wide range of fractionation schedules may be used, including less protracted fractionation schedules such as 30 Gy in 10 fractions, 20 Gy in 4 or 5 fractions, or 8 Gy in 1 fraction.

Following Resection of Primary MCC	RT Dosing
Adjuvant RT	
• Negative resection margins • Microscopically positive resection margins • Grossly positive resection margins and further resection not possible	50–56 Gy 56–60 Gy 60–66 Gy
No Previous Resection of Primary MCC	
Unresectable	60–66 Gy
Surgery refused by patient	60–66 Gy
Surgery would result in significant morbidity	60–66 Gy

MCC – NCCN Part 2

National Comprehensive Cancer Network®

NCCN Guidelines Version 1.2024
Merkel Cell Carcinoma

NCCN Guidelines Index
Table of Contents
Discussion

PRINCIPLES OF RADIATION THERAPY

General Treatment Information–Draining Nodal Basin

- **Treatment Information**
  - **Irradiation of in-transit lymphatics is recommended only when the primary site is in close proximity to the nodal bed.**
- **General Dosing Prescription**
  - **All doses are at 2 Gy/day standard fractionation.**
  - **In the palliative setting, a wide range of fractionation schedules may be used, including less protracted fractionation schedules such as 30 Gy in 10 fractions, 20 Gy in 4 or 5 fractions, or 8 Gy in 1 fraction.**

Node Dissection Status	RT Dosing
• No SLNB or LN dissection	
▸ Clinically evident lymphadenopathy	60–66 Gy[a,b]
▸ Clinically node negative, but at risk for subclinical disease	46–50 Gy
• SLNB without LN dissection	
▸ SLN negative — RT not routinely indicated[c]	Observation
▸ SLN positive	50–56 Gy
• After LN dissection with multiple involved nodes and/or ENE[d]	60–66 Gy

[a] LN dissection is the recommended initial therapy for clinically evident adenopathy, followed by postoperative RT if indicated.
[b] Shrinking field technique.
[c] Consider empiric RT to the nodal basin when: 1) the accuracy of SLNB may have been subject to anatomic compromise (lymphoma involved nodes, or history of remote LN excision); 2) when the risk of false-negative SLNB is high due to aberrant LN drainage and presence of multiple SLN basins (such as in head & neck or midline trunk MCC); or 3) when identified by lymphoscintigraphy in cases of profound immunosuppression (ie, solid organ transplant recipients).
[d] Adjuvant RT following LN dissection is only indicated for multiple involved nodes and/or the presence of ENE. Adjuvant RT following LN dissection is generally not indicated for patients with low tumor burden on SLNB or with a single macroscopic clinically detected LN without ENE.

MCC – PMCC 40 year outcomes

Wang *et al. BMC Cancer* (2023) 23:30
https://doi.org/10.1186/s12885-022-10349-1

BMC Cancer

RESEARCH Open Access

Merkel cell carcinoma: a forty-year experience at the Peter MacCallum Cancer Centre

Annie J. Wang[1], Brendan McCann[1*], William C. L. Soon[1], Paolo B. De Ieso[2], Mathias Bressel[3], Andrew Hui[4], Margaret Chua[1] and David L. Kok[1,5*]

Some centres have already taken this approach and recommend that in MCC with high risk factors (primary tumours >1 cm diameter, LVI, positive SLNB, chronic immunosuppression such as lymphoma/leukaemia, head and neck tumours) patients should not have re-excision in the setting of a close or positive margin if planned for adjuvant RT [11, 26]. In many Australian centres, including PMCC, the practice has gone one-step further and often RT is the primary modality of treatment for stage I-III MCC after histological diagnosis [11]. Ultimately, higher level evidence will be needed to definitively answer these questions on what is the optimal management pathway for patients with MCC.

MCC - Surveillance

- Clinical exam plus
- FDG-PET **or** CT C/A/P +/- H&N every 3-6 months for first 3 years then every 6-12 months for total of 5
- NCCN now endorses MCPyV oncoprotein monitoring – not yet standard in Alberta

- *"Quantitation of serum MCPyV oncoprotein antibodies may be considered as part of initial workup; patients who test seronegative may have a higher risk of recurrence; in patients who test seropositive, a rising titer may be an early indicator of recurrence; baseline testing should be performed within 3 months of treatment, because titers are expected to decrease significantly after clinically evident disease is eliminated."*



[c] Quantitation of serum MCPyV oncoprotein antibodies may be considered as part of initial workup; patients who test seronegative may have a higher risk of recurrence; in patients who test seropositive, a rising titer may be an early indicator of recurrence; baseline testing should be performed within 3 months of treatment, because titers are expected to decrease significantly after clinically evident disease is eliminated.

[d] As immunosuppression in MCC is a risk factor for poor outcomes, immunosuppressive treatments should be minimized as clinically feasible in consultation with the relevant managing physician. As patients who are immunocompromised are at high risk for recurrence, more frequent follow-up may be indicated.

[j] Imaging via FDG-PET/CT or CT with contrast of chest, abdomen, pelvis, and neck if primary on head/neck (and MRI of the brain with and without contrast if clinical suspicion of brain metastases or direct extension).

[k] Principles of Radiation Therapy (MCC-B).

[m] Appropriateness of RT should be determined by a radiation oncologist.

[n] Principles of Systemic Therapy (MCC-D).

[q] Under highly selective circumstances, in the context of multidisciplinary consultation, resection of limited metastases can be considered.

[r] Surveillance imaging is typically via diagnostic CT of chest/abdomen/pelvis with oral and IV contrast; neck CT is often included if primary lesion was on head/neck.

[s] Risk factors for recurrence include immunosuppression, advancing age, advancing stage of disease (stage II–IV), individuals assigned male at birth, non-SLN metastases, Merkel Cell polyomavirus negative status, as well as additional factors as determined by the treating physicians.

MCC - Immunotherapy

Journal of Dermatological Science 105 (2022) 2–10

Contents lists available at ScienceDirect

Journal of Dermatological Science

journal homepage: www.elsevier.com/locate/jdermsci

Invited review article

Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer

Tomoko Akaike[a,1], Paul Nghiem[a,b,*,2]

[a] Division of Dermatology, Department of Medicine, University of Washington, USA
[b] Fred Hutchinson Cancer Research Center, Seattle, USA





Fig. 2. Kaplan-Meier curves of patients with advanced Merkel cell carcinoma who were treated with immunotherapy as compared to historical cohorts of patients who were treated with chemotherapy. Panel A Overall survival (OS) of patients with chemotherapy-refractory MCC who were treated either with avelumab (anti-PDL1; brown-upper line) or with additional chemotherapy (red & blue lines; from two historical cohorts from the literature; Becker 2017 [23], Cowey 2017 [22]). Panel B Overall survival of patients who were treated with first-line pembrolizumab (anti-PD1) as compared to historical cohorts of patients who received first-line chemotherapy. Numbers that align with 6-month time periods indicate survival percentage for each cohort.
(a) Adapted, with permission, from Nghiem et al., ASCO 2021 [26]. (b) Adapted, with permission, from Nghiem et al., JCO 2019 [29].



Non-Melanoma Skin Cancers

SCC and BCC

Epidemiology – Geographic Variation



Figure 4. Lifetime risk for developing basal cell carcinoma in males (BCC[M]) and females (BCC[F]) and Squamous Cell Carcinoma in males (SCC[M]) and females (SCC[F]) in Manitoba, British Columbia, Alberta, New Brunswick, and the US.

Epidemiology – Incidence over time



Source: Ontario Cancer Registry, 2018 (Ontario Health [Cancer Care Ontario])

SCC and BCC Risk Factors

- Older age
- Higher UV exposure (UVB > UVA)
- Skin type
- Prior RT exposure
- Chronic inflammation (SCC>BCC)
- Chemical exposure
- Immune deficiency
  - Transplant
  - SLL/CLL

BCC, SCC Genetics

Gorlin syndrome

- (basal cell nevus syndrome, PTCHmt)
- Autosomal dominant
- Multiple BCCs, RMS, medulloblastoma, fibrosarcomas, palmar/plantar pits, frontal bossing, bifid ribs, bone cysts
- Classically, avoid irradiating these patients





Bazex-Dupre-Christol syndrome

- X-linked, dominant
- Multiple BCC and pitting ‘ice pick’ scars on the skin



Xeroderma pigmentosum

- Xeroderma pigmentosum:
  - X-linked
  - Increased sensitivity to UV radiation
  - 1000 increased risk of skin cancer (~57% lifetime risk)
  - Faulty NER repair



- Albinisim
  - 35% lifetime risk of skin cancer
- Muir-Torre syndrome
  - Autosomal dominant
  - Sebaceous skin tumours, eyelid, GI/GU malignancies
  - Associated with MSH-1 and MLH-1 (DNA MMR genes)



Muir-Torre syndrome

BCC Genetics

- >90% associated with abnormal hedgehog pathway signaling
- Vismodegib acts on the Sonic Hedgehog Pathway (SHH)

BCC Pathologies

- Nodular (60%) – papule
- Superficial (30%) – scaly macule
- Morpheaform (5-10%)
  - More likely to have infiltrating growth
- Infiltrative, Basoquamous (rare)
  - More aggressive, behave more similar to SCC

BCC Natural History

- Locally aggressive
- 0.1% PNI
  - CN V, VII most likely
- <1% metastasize

SCC Pathologies

- SCC in Situ – Bowen’s disease
- Superficial
- Spindle cell

SCC Natural history

- Actinic Keratosis is premalignant lesion
  - 6-10% of invasive SCC in 10 years if multiple AK's
- PNI ~10%
- ~5% metastases
  - P16 positive in ~1/3 but not prognostic

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Squamous-Cell Carcinoma of the Skin

Ashley Wysong, M.D.

From the Department of Dermatology, University of Nebraska Medical Center, Omaha. Dr. Wysong can be contacted at ashley.wysong@unmc.edu or at the Department of Dermatology, 985645 Nebraska Medical Center, Omaha, NE 68198.

N Engl J Med 2023;388:2262-73.
DOI: 10.1056/NEJMra2206348

CME at NEJM.org

SKIN CANCER IS THE MOST FREQUENTLY DIAGNOSED CANCER IN THE United States and worldwide. One in five Americans will have skin cancer in their lifetime.[1] Nonmelanoma skin cancers, also called keratinocyte carcinomas, are the most common type of cancer treated in the United States, with more than 5 million incident cases per year.[2] Precise estimates of incidence are challenging, since keratinocyte carcinoma is not reported in national cancer registries such as the Surveillance, Epidemiology, and End Results registry. Cutaneous squamous-cell carcinoma is the second most common type of skin cancer, with more than 1 million new cases per year,[2,3] outnumbering all top five reportable cancers treated in the United States combined.

The overall prognosis for patients with cutaneous squamous-cell carcinoma is excellent. Nodal metastases develop in 1.9 to 5.2% of cases, and overall mortality is 1.5 to 3.4%.[3-7] However, patients with metastases tend to have much poorer outcomes.[6] Among immunosuppressed patients, the risk of cutaneous squamous-cell carcinoma is increased by a factor of 65 to 250, with a higher incidence of local recurrence and metastasis in 6 to 15% of cases.[8,9] Cutaneous squamous-cell carcinoma accounts for an increasing number of deaths from skin cancer in the United States, with estimates suggesting that the absolute numbers of patients with nodal metastasis and of deaths are equal to or exceed those for melanoma or leukemia.[3,10] Both the incidence of cutaneous squamous-cell carcinoma and the burden of disease are on the rise. This evidence-based review provides clinicians with current information about epidemiologic features, clinicopathological risk factors, staging, management, and prevention.[2,11,12]



Figure 2. Clinical and Pathological Risk Factors for Local Recurrence and Metastasis in Patients with Cutaneous Squamous-Cell Carcinoma.

LVI denotes lymphovascular invasion, and PNI perineural invasion.

SCC Lymph Node Risk

- G1
  - LN~1%
- G3, >3cm, DOI >4mm, lips, and temporal lesions
  - LN~15%
- Originating in burn scar or osteomyelitis
  - LN~30%

SCC Distant Risk

- Brantsch Lan Onc ‘08
  - Prospective series
  - 615 patients, MFU ~4y
- Increased tumor thickness >6mm
- Immunosuppresion
- Location on the ear (up to 10% DM)
- Increased tumor diameter
  - <2cm, DM 1.9%
  - >2cm DM 7.5%
  - >5cm, DM 20%



TABLE 17.3: AJCC 8th ed. (2017) Staging System for Cutaneous Squamous Cell Carcinoma

T/M \ N		cN0	cN1	cN2a	cN2b	cN2c	cN3a	cN3b
T1	• <2 cm	**I**	**III**	**IVA**				
T2	• 2.1–4 cm	**II**						
T3	• >4 cm • 1 high risk feature[1]							
T4a	• Gross cortical bone	**IVA**						
T4b	• Invasion into skull base	**IVB**						
M1	• Distant metastasis	**IVC**						

Notes: 1 high risk feature[1] = Minor bone erosion, PNI (nerve measuring ≥0.1 mm), or deep invasion (beyond subcutaneous fat or >6 mm depth). Nodal category definition is similar to other non-HPV-associated head and neck cancers; see Table 10.4 for clinical and pathologic nodal categories.

TABLE 17.4: Brigham and Women's Hospital Staging System for Cutaneous Squamous Cell Carcinoma

		10-yr LR		High-Risk Factors
T1	0 High-risk factors	0.6%		Tumor ≥2 cm
T2a	1 High-risk factor	5%		Poor differentiation
T2b	2–3 High-risk factors	21%		PNI ≥0.1 mm
T3	≥4 High-risk factors	67%		Tumor beyond fat (bone invasion automatically T3)

Prognosis - Karia, JCO 2014



Table 1. Tumor Staging and Risk Factors for Cutaneous Squamous-Cell Carcinoma.

Tumor Stage	Staging System*				
	AJCC	BWH	Salamanca Refinement	Tübingen	NCCN
Low risk					
T1	Tumor diameter <2 cm	0 risk factors	Tumor diameter <2 cm	Tumor diameter ≤2 cm, tumor thickness ≤6 mm	Tumor diameter ≤2 cm on trunk and arms and legs; well-defined, primary tumor, well or moderately differentiated, depth ≤6 mm
T2	Tumor diameter ≥2 cm and <4 cm		Tumor diameter ≥2 cm and <4 cm		
T2a		1 risk factor			
High risk					
T2b		2 or 3 risk factors			**High risk**: tumor diameter >2 cm and ≤4 cm on trunk and arms and legs; location on head, neck, hands, or feet, pretibial area, or anogenital areas, regardless of diameter; poorly differentiated, recurrent, immunosuppression, site of prior radiation therapy or chronic inflammatory process, rapid growth, neurologic symptoms, perineural involvement. **Very high risk**: tumor diameter >4 cm at any location, poor differentiation, desmoplastic squamous-cell carcinoma, depth >6 mm or invasion below subcutaneous fat, perineural invasion of a nerve lying below dermis or measuring ≥0.1 mm, lymphatic or vascular invasion
T3	Tumor diameter ≥4 cm or minor bone erosion, perineural invasion, or deep invasion	≥4 high-risk factors or bone invasion			
T3a			Tumor thickness >6 mm (with no invasion beyond subcutaneous fat), with or without tumor diameter ≥4 cm		
T3b			Invasion beyond subcutaneous fat or perineural invasion		
T3c			Combination of both T3b risk factors or AJCC T3 definition with ≥3 risk factors		
T4a	Tumor with gross cortical bone or marrow invasion				
T4b	Tumor invading skull bone or involving skull base foramen				

* The American Joint Committee on Cancer (AJCC) *Cancer Staging Manual*, 8th edition, defines deep invasion as invasion beyond subcutaneous fat or at a depth of more than 6 mm. Perineural invasion is defined as invasion in nerves that are 0.1 mm or more in diameter, invasion that is deeper than the dermis, or clinical and radiologic involvement of affected nerves, without involvement or invasion of the base of the cranium. The Brigham and Women's Hospital (BWH) staging system defines high-risk tumors as having a diameter of 2 cm or greater, poorly differentiated histologic features, perineural invasion of 0.1 mm or more, or tumor invasion beyond subcutaneous fat (excluding bone invasion, which automatically upgrades the tumor to stage T3). NCCN denotes National Comprehensive Cancer Network.

Surgery or RT?



Figure 1 Kaplan–Meier plot of recurrent or persistent BCC in patients treated with surgery or radiotherapy. Bars indicate 95% confidence intervals. - - -, Surgery (n = 174, one event); —, radiotherapy (n = 173, 11 events)

British Journal of Cancer (1997) **76**(1), 100–106

Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study

M-F Avril[1], A Auperin[2], A Margulis[3], A Gerbaulet[4], P Duvillard[5], E Benhamou[2], J-C Guillaume[6], R Chalon[1], J-Y Petit[7], H Sancho-Garnier[8], M Prade[5], J Bouzy[2] and D Chassagne[4]

[1]Service de dermatologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France; [2]Départements de [2]biostatistique et d'épidémiologie, [3]chirurgie générale, [4]radiothérapie and [5]anatomopathologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France; [6]Service de dermatologie, Centre Hospitalier Louis Pasteur, 68021 Colmar Cedex, France; [7]Service de chirurgie plastique, Institut Européen d'Oncologie, Via Ripamonti 435, 20141 Milan, Italie; [8]Epidaure, Parc Euromédecine, 34298 Montpellier Cedex 5, France

Among the 173 patients in the radiotherapy group, 95 were treated with interstitial brachytherapy, 57 with contactherapy, 20 with conventional radiotherapy and one with surgery. Contactherapy was applied to smaller BCCs (8.4 mm, s.d. = 3.2), brachytherapy used for intermediate sized BCCs (12.9 mm, s.d. = 5.8) and conventional radiotherapy for the largest BCCs (15.5 mm, s.d. = 5.8).

For brachytherapy, the silk suture technique was used in 87 cases. The range of the doses delivered was 57–76 Gy. Forty-five patients received 65 Gy and 27 received 70 Gy. Most of the time, two or three radioactive lines were used (70 and 23 patients respectively). Local anaesthesia was performed in 80 patients. The mean duration of hospitalization was 6.9 days (s.d. = 1.8).

The range of the dose delivered by contactherapy was 34–40 Gy, with two-thirds of the patients receiving 36 Gy.

The doses delivered by conventional radiotherapy were 60 Gy in 18 cases, 65 Gy in one case and 33 Gy in another case. The duration of treatment varied 5–7 weeks.

Comparing Modalities

Technique	Low risk LC	High Risk LC
Surgical excision with post operative margin assessment	90-95%	83-88%
Mohs	99%	90-94%
RT	90-96%	80-88%

More details in recent metaanalysis - Lee et al, Cancer 2020

ASTRO Guidelines – Likhacheva, PRO 2019

Key questions and recommendations:

- Indications for definitive RT
- Indications for postoperative RT
- Indications for treating regional nodes and regional disease management
- Radiation techniques and dose-fractionation schedules for primary site management
- Use of chemotherapy, biologic, and immunotherapy agents before, during, or after RT

Table 4. Recommendations for definitive RT

KQ1 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)
1. In patients with BCC and cSCC who cannot undergo or decline surgical resection, definitive RT is recommended as a curative treatment modality.	Strong	Moderate [3-8]
2. In patients with BCC and cSCC in anatomical locations where surgery can compromise function or cosmesis, definitive RT is conditionally recommended as a curative treatment modality.	Conditional	Moderate [9-11]
3. Definitive RT for BCC and cSCC is conditionally **not** recommended in patients with genetic diseases predisposing to heightened radiosensitivity.	Conditional	Expert Opinion

Abbreviations: BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; KQ = key question; RT = radiation therapy.

Definitive RT

- Central lesions >5mm
  - Nasal ala
  - Eyelids
  - Tip of nose
  - Lip commissure
- Lesions >2cm
  - Forehead
  - Scalp

- (relative) contraindications
  - Poor blood supply or high trauma
    - Dorsum of hand
    - Belt line
    - Shin
  - Previous RT to area
  - Exposed cartilage/bone
  - Gorlin syndrome
  - XP

Table 5. Recommendations for PORT

KQ2 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)
Both BCC and cSCC		
1. PORT is recommended for gross perineural spread that is clinically or radiologically apparent.	Strong	Moderate [29,33-36]
cSCC		
2. PORT is recommended for patients with cSCC having close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome).	Strong	Low [37]
3. PORT is recommended for patients with cSCC in the setting of recurrence after a prior margin-negative resection.	Strong	Moderate [38-43]
4. In patients with cSCC, PORT is recommended for T3 and T4 tumors.*	Strong	Moderate [44-46]
5. In patients with cSCC, PORT is recommended for desmoplastic† or infiltrative tumors in the setting of chronic immunosuppression.	Strong	Moderate [44,46]
BCC		
6. PORT is conditionally recommended in patients with BCC with close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome).	Conditional	Low [8,24]
7. PORT is conditionally recommended in patients with BCC in the setting of recurrence after a prior margin-negative resection.	Conditional	Low [8,24,47,48]
8. PORT is conditionally recommended in patients with BCC with locally advanced or neglected tumors involving bone or infiltrating into muscle.	Conditional	Low [8,24,45]

Abbreviations: BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; KQ = key question; PORT = postoperative radiation therapy; RT = radiation therapy.

* American Joint Committee on Cancer staging table, eighth edition.[2]

† The presence of desmoplasia on light microscopy is defined as fine branches of tumor cells at the periphery and a surrounding stromal reaction. All cSCC in which at least one-third of the representative tumor specimen meet these criteria is classified as desmoplastic cSCC. One study reported findings that perineural or perivascular invasion were always associated with desmoplasia.[46]

Notable guideline updates - 2023

European Journal of Cancer 193 (2023) 113251

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

Original Research

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

Alexander J. Stratigos [a,*], Claus Garbe [b], Clio Dessinioti [a], Celeste Lebbe [c], Alexander van Akkooi [d,e,f], Veronique Bataille [g], Lars Bastholt [h], Brigitte Dreno [i], Reinhard Dummer [j], Maria Concetta Fargnoli [k], Ana Maria Forsea [l], Catherine A. Harwood [m], Axel Hauschild [n], Christoph Hoeller [o], Lidija Kandolf-Sekulovic [p], Roland Kaufmann [q], Nicole WJ Kelleners-Smeets [r,s], Aimilios Lallas [t], Ulrike Leiter [b], Josep Malvehy [u], Veronique del Marmol [v], David Moreno-Ramirez [w], Giovanni Pellacani [x], Ketty Peris [y,z], Philippe Saiag [aa], Luca Tagliaferri [ab], Myrto Trakatelli [ac], Dimitrios Ioannides [t], Ricardo Vieira [ad], Iris Zalaudek [ae], Petr Arenberger [af], Alexander M.M. Eggermont [ag,ah], Martin Röcken [b], Jean-Jacques Grob [ai], Paul Lorigan [aj,ak], On behalf of EADO, EDF, ESTRO, UEMS, EADV and EORTC [1]

[a] First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece
[b] Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
[c] Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, Cancer Institute APHP. Nord-Université Paris Cite, INSERM U976, Paris, France
[d] Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
[e] Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
[f] Melanoma Institute Australia, Sydney, New South Wales, Australia
[g] Mount Vernon Cancer Centre, East and North NHS Trust, Northwood, UK
[h] Department of Oncology, Odense University Hospital, Odense, Denmark
[i] Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France
[j] Skin Cancer Centre at University Hospital Zurich, Zurich, Switzerland

European Journal of Cancer 193 (2023) 113252

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

Original Research

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

Alexander J. Stratigos [a,*], Claus Garbe [b], Clio Dessinioti [a], Celeste Lebbe [c], Alexander van Akkooi [d,e,f], Veronique Bataille [g], Lars Bastholt [h], Brigitte Dreno [i], Reinhard Dummer [j], Maria Concetta Fargnoli [k], Ana Maria Forsea [l], Catherine A. Harwood [m], Axel Hauschild [n], Christoph Hoeller [o], Lidija Kandolf-Sekulovic [p], Roland Kaufmann [q], Nicole WJ Kelleners-Smeets [r,s], Aimilios Lallas [t], Ulrike Leiter [b], Josep Malvehy [u], Veronique del Marmol [v], David Moreno-Ramirez [w], Giovanni Pellacani [x], Ketty Peris [y,z], Philippe Saiag [aa], Luca Tagliaferri [ab], Myrto Trakatelli [ac], Dimitrios Ioannides [t], Ricardo Vieira [ad], Iris Zalaudek [ae], Petr Arenberger [af], Alexander M.M. Eggermont [ag,ah], Martin Röcken [b], Jean-Jacques Grob [ai], Paul Lorigan [aj,ak], On behalf of EADO, EDF, ESTRO, UEMS, EADV and EORTC [1]

[a] First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece
[b] Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
[c] Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, Cancer Institute APHP. Nord-Université Paris Cite, INSERM U976, Paris, France
[d] Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
[e] Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
[f] Melanoma Institute Australia, Sydney, New South Wales, Australia
[g] Mount Vernon Cancer Centre, East and North NHS Trust, Northwood, UK
[h] Department of Oncology, Odense University Hospital, Odense, Denmark

Box 10 Adjuvant RT for resected nodal metastatic cSCC.

Adjuvant RT for resected nodal cSCC	Evidence-based recommendation
Grade of recommendation B	Adjuvant radiotherapy following therapeutic lymphadenectomy should be considered in cSCC of the head and neck with regional nodal metastases and extracapsular extension.
Level of evidence 3	Meta-analysis (20 observational studies and 1 randomized phase III study) [48]. Randomized phase III study [96]. Retrospective studies [47,81,97]. Guideline [95]. Strength of consensus: 100%.

Box 11 Adjuvant RT for high-risk cSCC.

Adjuvant RT	Evidence-based recommendation
Grade of recommendation C	Adjuvant radiotherapy may not be offered as standard of care for cSCC with clear surgical margins, as a clear benefit has not been shown.
Level of evidence 3	Retrospective studies [89,91,92]. Meta-analysis [90]. Strength of consensus: 100%.
Grade of recommendation C	Adjuvant radiotherapy may be discussed for cSCC with multiple high-risk factors (BWH T2b/T3) and with clear surgical margins.
Level of evidence: 4	Retrospective study [94]. Strength of consensus: 97%.

Box 12 Immunotherapy for advanced cSCC.

Immunotherapy for locally advanced or metastatic cSCC	Evidence-based recommendation
Grade of recommendation B	Patients with metastatic cSCC or locally advanced cSCC, who are not candidates for curative surgery or curative radiation, should receive first-line treatment with a PD-1 antibody*.
Level of evidence 2	Phase 1 and 2 study of cemiplimab. [115,119–121]. Phase 1 and 2 of pembrolizumab. [124,125,127,130]. Strength of consensus: 100%.

* In Europe, cemiplimab is currently the only approved medication, while pembrolizumab and nivolumab are investigated in clinical studies.



Fig. 1. Proposed treatment algorithm for patients with cSCC. Strength of consensus: 90%. [a]For detailed indications and recommendations of treatment, refer to the relevant section text in the Guidelines. [b]Locally advanced by definition not amenable to curative surgery or RT. Micrographically controlled surgery instead of sectional assessment is advised, when available. [d] Lymph node dissection as indicated. [e]In Europe, all systemic treatments are off-label, except for the anti-PD-1 agent cemiplimab that is approved by EMA for patients with locally advanced or metastatic cSCC who are not candidates for curative surgery or curative radiotherapy. cSCC, cutaneous squamous cell carcinoma; MCS, micrographically controlled surgery; RT, radiotherapy.

Indications for Adjuvant RT

- Primary
  - Margin+
  - Extensive PNI
    - >0.1=mm nerve or widespread/multiple involvement
  - pT3-4
  - SCC mets to parotid
- Nodes
  - ECE
    - Can consider surveillance in pN2a so long as ECE not present
  - ENI if recurrent after surgery
  - G3, >3cm, and/or large infiltrative-ulcerative SqCC
  - Consider parotid coverage (if intact) for post op face

Adjuvant RT for PNI?

INTRODUCTION

Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer, accounting for 20% to 50% of all skin cancers.[1] The incidence of cSCC is continuing to rise with increases of 50% to 200% reported over the past 3 decades.[2-4] Although 96% of cSCCs can be treated successfully with wide local excision or Mohs micrographic surgery, there is a subset of cSCCs that are associated with higher rates of local recurrence, metastasis, and disease-specific death.[5,6] High-risk features for this subset of cSCCs include tumor diameter of >2 cm, perineural invasion (PNI) of nerves >0.1 mm in caliber, tumor depth beyond subcutaneous fat, poorly differentiated histology, the previously irradiated or recurrent tumor, location in the ear or the lip, tumor arising within scar, and immunosuppression.[7-9]

The role of adjuvant radiotherapy for these high-risk cSCCs remains unclear. Current National Comprehensive Cancer Network (NCCN)

CAPSULE SUMMARY

- The indications for adjuvant radiotherapy after margin-negative resection for high-risk cutaneous squamous cell carcinomas are unclear.
- This meta-analysis found that adjuvant radiotherapy did not significantly change local recurrence, nodal metastases, regional metastases, and disease-specific death. Randomized controlled trials are necessary to define the benefit of adjuvant radiotherapy in this setting.

Evidence acquisition

The population, intervention, control, outcome, and study design method was used to define literature inclusion criteria (Supplementary Table I, available via Mendeley at https://data.mendeley.com/datasets/ytmw6yncpn/1).[12-14] The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines[15] and the Meta-analysis of Observational Studies in Epidemiology reporting guidelines[16] were used (Supplementary Fig 1, available via Mendeley at https://data.mendeley.com/datasets/ytmw6yncpn/1). A comprehensive and systematic search of PubMed/MEDLINE, Embase, and the Cochrane Database of Systematic Reviews from 2006 to 2020 was performed by 2 experienced librarians with input from the study's principal investigator (CL) and the lead author (YK). Literature published before 2006

Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis

Yesul Kim, MD,[a] Eric J. Lehrer, MD, MS,[b] Paul J. Wirth, MD,[a] Eiman A. Khesroh, MBBS, MPH,[c] Jerry D. Brewer, MD, MS,[d] Elizabeth M. Billingsley, MD,[a] Nicholas G. Zaorsky, MD, MS,[e] and Charlene Lam, MD, MPH[a]

Hershey, Pennsylvania; New York, New York; Rochester, Minnesota; and Fairport Harbor, Ohio

Table 7. Recommendations for radiation techniques and dose-fractionation schedules for primary site management

KQ4 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)
1. In patients with BCC and cSCC receiving RT in the definitive setting, the following dose-fractionation schemes* are recommended: ○ Conventional (180–200 cGy/fx): BED_{10} 70–93.5 ○ Hypofractionation (210–500 cGy/fx): BED_{10} 56–88 **Implementation Remark**: Conventional fractionation is delivered 5 days per week; hypofractionation is delivered daily or 2-4 times per week.	Strong	Low 10,79,80,82,88-94
2. In patients with BCC and cSCC receiving RT in the postoperative setting, the following dose-fractionation schemes* are recommended: ○ Conventional (180–200 cGy/fx): BED_{10} 59.5–79.2 ○ Hypofractionation (210-500 cGy/fx): BED_{10} 56–70.2 **Implementation Remark:** Conventional fractionation is delivered 5 days per week; hypofractionation is delivered daily or 2-4 times per week.	Strong	Low 5,48,90,93,95-100

Abbreviations: BCC = basal cell carcinoma; BED_{10} = biologically effective dose assuming an $\alpha/\beta = 10$; cSCC = cutaneous squamous cell carcinoma; fx = fraction; KQ = key question; RT = radiation therapy.

* See Table 8 with specific fractionation schemes.

Figure 2. Dose fractionation summary

Dose (cGy) \ # of Fractions	8	9	10	11	14	15	16	17	18	20	28	30	33	35	36
180											5040		5940		6480
200												6000	6600	7000	
250										5000					
275										5500					
300					4200	4500	4800	5100	5400						
340									6120						
400				4400											
440			4400												
450		4050	4500												
500	4000														

OLD – Dosing in Gy

PRINCIPLES OF RADIATION THERAPY

General Principles

- Protracted fractionation is associated with improved cosmetic results and should be utilized for poorly vascularized or cartilaginous areas.
- For extensive perineural invasion, clinically evident perineural involvement, or involvement of named nerves (particularly in the head and neck region), consider including the course of the local nerves proximally.
- RT is contraindicated for genetic conditions predisposing to skin cancer (eg, basal cell nevus syndrome) and relatively contraindicated for patients with connective tissue diseases (eg, scleroderma).
- Given higher complication rates, re-irradiation should not be routinely utilized for recurrent disease within a prior radiation field.
- Isotope-based brachytherapy can be an effective treatment for certain sites of disease, particularly on the head and neck.
- There are insufficient long-term efficacy and safety data to support the routine use of electronic surface brachytherapy.

General Treatment Information

Primary Tumor	Examples of Dose Fractionation and Treatment Duration
Definitive RT	
Tumor diameter <2 cm	60–64 Gy over 6 to 7 weeks 50–55 Gy over 3 to 4 weeks 40 Gy over 2 weeks 30 Gy in 5 fractions over 2 to 3 weeks
Tumor diameter ≥2 cm, T3/T4, or those with invasion of bone or deep tissue	60–70 Gy over 6 to 7 weeks 45–55 Gy over 3 to 4 weeks
Postoperative Adjuvant RT	60–64 Gy over 6 to 7 weeks 50 Gy over 4 weeks
Regional Disease	
• Lymph node regions, after lymph node dissection	
▸ Negative margins, no ECE	50–60 Gy over 5 to 6 weeks
▸ Positive margins or ECE	60–66 Gy over 6 to 7 weeks
• Lymph node regions, without lymph node dissection	
▸ Clinically negative, at risk	50 Gy over 5 weeks
▸ Clinically positive	60–70 Gy over 6 to 7 weeks
• Clinically at-risk nerves	50–60 Gy over 5 to 6 weeks

CURRENT – Dosing in BED

PRINCIPLES OF RADIATION THERAPY

General Principles[a]

- Protracted fractionation is associated with improved cosmetic results and should be utilized for poorly vascularized or cartilaginous areas.
- For extensive perineural invasion, clinically evident perineural involvement, or involvement of named nerves (particularly in the head and neck region), consider including the course of the local nerves proximally.
- In the setting of clinically evident perineural invasion (PNI) (or if grossly radiographically involved) for head and neck CSCCs, comprehensive coverage of involved cranial nerve pathways in addition to proximal local nerves should be considered.
- RT is contraindicated for genetic conditions predisposing to skin cancer (eg, basal cell nevus syndrome) and relatively contraindicated for patients with connective tissue diseases (eg, scleroderma).
- Given higher complication rates, re-irradiation should not be routinely utilized for recurrent disease within a prior radiation field.
- Isotope-based brachytherapy can be an effective treatment for certain sites of disease, particularly on the head and neck.
- There are insufficient long-term efficacy and safety data to support the routine use of electronic surface brachytherapy.

General Treatment Information

- Radiation treatments should be given by a practicing radiation oncologist with radiation physics support to meet established quality assurance and dosimetric constraints.

Primary Tumor	RT Dosing
Definitive RT	BED10 of 70–93 Gy for conventional fractionation BED10 of 56–88 Gy for hypofractionation
Postoperative Adjuvant RT[1]	BED10 of 60–79 Gy for conventional fractionation BED10 of 56–70 Gy for hypofractionation
Regional Disease	
• Lymph node regions, after lymph node dissection	
▸ Negative margins, no ECE	50–60 Gy over 5 to 6 weeks
▸ Positive margins or ECE	60–66 Gy over 6 to 7 weeks
• Lymph node regions, without lymph node dissection	
▸ Clinically negative, at risk	50 Gy over 5 to 7 weeks
▸ Clinically positive	60–70 Gy over 6 to 7 weeks
• Clinically at-risk nerves	50–60 Gy over 5 to 6 weeks

Dosing – UK Survey, McPartlin, BJR 2014

Table 1. Popularity of commonly suggested dose fractionations

Dose fractionation	Number of times suggested
18 Gy/1#	41
20 Gy/1#	18
32 Gy/5#	27
35 Gy/5#	237
40.5 Gy/9#	22
40 Gy/10#	29
45 Gy/10#	170
45 Gy/9#	51
45 Gy/15#	15
50 Gy/15#	56
50 Gy/20#	57
55 Gy/20#	134
60 Gy/30#	26
66 Gy/33#	11
27 Gy/3# over 2 weeks	20
28 Gy/2# over 6 weeks	11
38 Gy/6# over 6 weeks	11
45 Gy/9# over 3 weeks	24

Figure 1. Fractionation regimes employed for a given scenario in different patient groups. BCC, basal cell carcinomas; SCC, squamous cell carcinomas.



Figure 2. Radiation modality employed for given scenario in different patient groups. BCC, basal cell carcinomas; kv, kilovoltage; SCC, squamous cell carcinomas.



How to choose?

- Can only treat with what you have available
- If you have choice, is a balance between
  - Practicality
  - Resources
  - Toxicity/Anatomy
- Need to know both orthovoltage and electrons well for your exams

Post operative head and neck guidelines – IJROBP 2020

Clinical Investigation

Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Sandro V. Porceddu, MBBS, FRANZCR, MD,[*,†] Christopher Daniels, MBBS, FRANZCR,[*] Sue S. Yom, MD, PhD,[‡] Howard Liu, MBBS, FRANZCR,[*,†] John Waldron, MD, FRCPC, MSc,[§,‖] Vincent Gregoire, MD, PhD,[¶] Alisha Moore, BMedRadSci(RT),[#,**] Michael Veness, MBBS, MD, MMed (Clin Epi), FRANZCR,[††,‡‡] Min Yao, MD, PhD,[§§] Jorgen Johansen, MD, PhD,[‖‖] Hisham Mehanna, PhD, BMedSc, MB ChB, FRCS, FRCS (ORL-HNS),[¶¶] Danny Rischin, MBBS, FRACP, MD,[##,***] and Quynh-Thu Le, MD[†††]

*Princess Alexandra Hospital, Brisbane, Australia; [†]University of Queensland, Queensland, Australia; [‡]University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California; [§]Princess Margaret Cancer Centre, Toronto, Canada; [‖]University of Toronto, Toronto, Canada; [¶]Centre Leon Berard, Lyon, France; [#]Trans Tasman Radiation Oncology Group, Newcastle, Australia; **University of Newcastle, Newcastle, Australia; [††]Westmead Hospital, Westmead, Australia; [‡‡]University of Sydney, Sydney, Australia; [§§]Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio; [‖‖]Odense University Hospital, Denmark; [¶¶]University of Birmingham, United Kingdom; [##]Peter MacCallum Cancer Center,

Post Operative Volumes

Table 1 Summary of target volume definitions

Target volume	Structure	Definition
Site of primary tumor before excision*	HRTVp	The volume that represents the preoperative primary site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings
Site of involved lymph nodes before excision*	HRTVn	The volume that represents the preoperative regional nodal site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings
Subsite of the HRTVp likely to carry a higher burden of microscopic disease (ie, positive or margin clearance <2 mm) and warranting a boost dose	HRTVp_Boost	The subvolume that represents the preoperative primary site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings and considered at particularly high risk
Subsite of the HRTVn disease likely to carry a higher burden of microscopic disease (ie, positive margin or extranodal extension)	HRTVn_Boost	The volume that represents the preoperative regional nodal site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings and considered at particularly high risk
Primary site high-risk clinical target volume	CTVp_HR	Minimum volume includes HRTVp + 5 mm isotropic expansion and modified to anatomic barriers. May also include the entire operative bed, reconstruction flap, or graft site. Resected LNPNS
Nodal site high-risk clinical target volume	CTVn_HR	Minimum volume includes HRTVn + 5 mm isotropic expansion and modified to anatomic barriers. May also include the entire involved neck node level/basin or neck dissection/parotidectomy bed
Primary site lesser risk clinical target volume	CTVp_LR	The primary site operative bed that does not meet the criteria for CTVp_HR and modified to anatomic barriers. May also include the broader operative bed, reconstruction flap, or graft site. For LNPNS it also includes the undissected zone proximal to the involved zone
Nodal site lesser risk clinical target volume	CTVn_LR	The nodal dissection operative bed that does not meet the criteria for CTVn_HR, modified to anatomic barriers, and next echelon of surgically undisrupted clinically uninvolved nodes (elective)
Primary tumor boost site (optional)	CTVp_HR_Boost	Minimum volume includes HRTVp_Boost + 5 mm expansion and modified to anatomic barriers
Nodal site boost site (optional)	CTVn_HR_Boost	Minimum volume includes HRTVn_Boost + 5 mm expansion and modified to anatomic barriers

Abbreviations: CT = computed tomography; CTV = clinical target volume; GTV = gross tumor volume; HR = high risk; HRTV = high-risk tumor volume; LNPNS = large nerve perineural spread; LR = low risk; n = nodal; p = primary.

* Where there is substantial overlap of the HRTVp and HRTVn, a single HRTV termed HRTVp/n may be used (eg, an extensive primary lesion over the preauricular area with underlying intraparotid nodal metastases).

Post Operative Doses

Table 2 Summary of recommended minimum prescribed doses*

Target volume	IMRT technique	Non-IMRT technique
PTVp_HR and/or PTVn_HR	60.0 Gy in 30 fractions	60.0 Gy in 30 fractions
PTVp_LR and/or PTVn_LR	56.0 Gy in 30 fractions Optional: 54.0 Gy in 30 fractions for surgically undisrupted LR region	54.0 Gy in 27 fractions Optional: 50.0 Gy in 25 fractions for surgically undisrupted LR region
PTVp_boost and/or PTVn_boost (optional)	66.0 Gy in 33 fractions or 63.0 Gy in 30 fractions	66.0 Gy in 33 fractions

Abbreviations: HR = high risk; IMRT = intensity modulated radiation therapy; LR = lesser risk; n = nodal involvement; p = primary site; PTV = planning target volume.

* Fractionation schedules are described as once daily at 5 fractions per week.

Variance exists, and ok to use SIB with slight hypofraction at RO's discretion (ie 63-66Gy/ 30-33 fr) – see last line

Lymph Nodes

Level of pathologically confirmed lymph node metastases	**Suggested CTVn_LR**
Pathologic involvement of intra-parotid lymph node following parotidectomy without neck dissection	Undissected ipsilateral levels Ib-III. *Some centres include IVa/b +/- Va*
Pathologic involvement of lymph nodes following upper (e.g. I-III) neck dissection	Undissected ipsilateral levels IVa/b-Va/b
Pathologic involvement of lymph nodes in the lower neck IVa/b-Va following neck dissection	Undissected levels Vb-Vc

Location of primary site	**Suggested first echelon lymph node station**
Superior Cheek	Ipsilateral Parotid (VIII)
Inferior Cheek	Ipsilateral Facial (IX); Submandibular (Ib); Parotid (VIII)
Lateral Forehead	Ipsilateral Parotid (VIII)
Hair-bearing upper lip	Bilateral Facial (IX); Submandibular (Ib); Submental (Ia)
Hair-bearing lower lip	Bilateral Submandibular (Ib); Submental (Ia)
Ear helix	Ipsilateral Parotid (VIII); Retroauricular (Xb)
Lateral Scalp	Ipsilateral Parotid (VIII), Retroauricular (Xb), Posterior triangle (Va)
Posterolateral Scalp	Ipsilateral Occipital (Xa), Retroauricular (Xb), Posterior triangle (Va)
Scalp vertex	Drainage can be unilateral or bilateral to Parotid (VIII) and also Retroauricular (Xb), Occipital (Xa)

Lymph Nodes



Illustration of cervical lymph node groups and lymphatic drainage pattern from cutaneous regions (purple arrows) and between nodal groups (green and brown arrows). Adapted from *Lengelé B, Hamoir M, Scalliet P, et al. Anatomical bases for the radiological delineation of lymph node areas. Major collecting trunks, head and neck. Radiother Oncol. 2007;85(1):146–55.*

Nerve coverage

- *Optionally, where there is extensive pathologic perineural invasion of nerves ≥ 0.1 mm diameter or multifocal peri- neural invasion but no clinical or radiologic evidence of large nerve PNS, zone I of the nearby (within 10-20 mm) named nerve may be included in low risk CTV*
- *If there is only zone 1 involvement of the infraorbital nerve (V2), the high risk CTV may include a 5-mm isotropic expansion of the involved infraorbital nerve, operative bed, and the region back to the pterygopalatine fossa and foramen rotundum.*
- *In cases where there is extensive involvement of the facial nerve within the parotid bed, the auriculotemporal and mandibular nerve back to the foramen ovale may be considered part of the CTVp_HR.*

Table 5. Cranial nerve zonal classification of trigeminal (V) and facial (VII) nerves

Nerve	Zone 1 (peripheral)	Zone 2 (central)	Zone 3 (cisternal)
V1	Superomedial orbit at the level of the orbital ridge up to SOF	SOF up to trigeminal ganglion cistern	Cistern of trigeminal ganglion (Meckel's Cave) to the brainstem
V2	Fat plane of periantral soft tissues, infraorbital canal and the pterygopalatine fossa up to FR	FR up to trigeminal ganglion cistern (Meckel's cave)	
V3	Inferior alveolar/lingual nerve up to FO	FO up to trigeminal ganglion cistern (Meckel's cave)	
VII	Branches of VII within the parotid gland up to SMF	SMF through and including labyrinthine segment up to IAC	IAC to the brainstem

V1 = ophthalmic division of the trigeminal nerve; V2 = maxillary division of the trigeminal nerve; V3 = mandibular division of the trigeminal nerve; VII = facial nerve; SOF = superior orbital fissure; FR = foramen rotundum; FO = foramen ovale; SMF = stylomastoid foramen; IAC = internal acoustic canal

As described in: Williams LS, Mancuso et al 2001 (25)

H Zone



BMJ

BMJ 2012;345:e5342 doi: 10.1136/bmj.e5342 (Published 21 August 2012)

CLINICAL REVIEW

Facial basal cell carcinoma

TROG 05.01 – RT +- carboplatin

VOLUME 36 · NUMBER 13 · MAY 1, 2018

JOURNAL OF CLINICAL ONCOLOGY | ORIGINAL REPORT

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial

Sandro Virgilio Porceddu, Mathias Bressel, Michael Geoffrey Poulsen, Adam Stoneley, Michael John Veness, Lizbeth Moira Kenny, Chris Wratten, June Corry, Stephen Cooper, Gerald Blaise Fogarty, Marnie Collins, Michael Kevin Collins, Andrew Martin John Macann, Christopher Gerard Milross, Michael Gordon Penniment, Howard Yu-hao Liu, Madeleine Trudy King, Benedict James Panizza, and Danny Rischin



Fig 2. Kaplan-Meier estimates of (A) freedom from locoregional relapse, (B) disease-free survival, and (C) overall survival by treatment arm. CRT, chemoradiotherapy; RT, radiotherapy.

Table 1: Systemic Therapy Options for Use with RT		
Preferred Regimens	**Other Recommended Regimens**	**Useful in Certain Circumstances**
• Cisplatin[2] • Clinical trial[3,4]	• None	• EGFR inhibitors (eg, cetuximab)[2] • Cisplatin + 5-FU[2] • Carboplatin ± paclitaxel[2,5,6]

NCCN - Concurrent options

Treatment Planning Considerations

CTV Margins

- BCC
  - Well defined, <2cm
    - 0.5-1.0cm
  - >2cm
    - 1-1.5cm
  - Use the larger CTV for infiltrative, poorly defined histologies
  - 0.5cm minimum depth
- SCC
  - Well defined, <2cm
    - 1.0cm
  - High risk features, >2cm
    - 1-**1.5cm**

Need to tailor to patient, anatomy, technique, and fractionation!
IJROBP Khan et al 2011
Rad & Onc Khan et al 2012

What about PTV?

- PTV/penumbra depends on technique
- IMRT
  - PTV +3-5mm depending on setup, IGRT
- Encroaching on OARs (eg near orbit, ocular structures) can consider FSRT IGRT with 2mm margins
- ICRU model breaks down somewhat for clinical setups
- Electrons
  - +5-10mm for penumbra
- Orthovoltage
  - PTV/Penumbra 2-3mm, though often collimated to ~CTV

Orthovoltage	Electrons
Advantages: • Better beam flatness • Sharper penumbra • Maximum dose at skin • Smaller margin • Smaller fields • No bolus	**Advantages:** • No F – factor • Greater depth dose with appropriate energy to treat large or thick lesions • Can have sharper fall off/less exit dose than orthovoltage if prescribed appropriately
Disadvantages: • High bone absorption (F-factor/photo electric effect) • Limited penetration/not ideal for thick or deep lesions	**Disadvantages:** • Dosimetry may be more complex • Skin sparing effect, need bolus for surface dose at lower energies • Larger field size • Electron back scatter • RBE effects

Stand-off correction factor



Fig 16.3 (a) Positive stand-off of 0.5 cm between lesion and applicator. (b) Negative stand-off of 0.5 cm.

Orthovoltage PDD



F-Factor

Cartilage: The 'F'-Factor Fallacy

P. Atherton[1], J. Townley[2] and J. Glaholm[1]

Departments of [1]Oncology and [2]Medical Physics and Biomedical Engineering, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK



Fig. 1. 'F'-factors for bone, cartilage and skin for photon energies from 10 keV to 80 keV.

- Measured f-factor for uncalcified cartilage is essentially equivalent to skin
- Don't forget – 150kVp has mean energy of ~50kV

Case 1 – BCC of Anterior Pinna



- 1cm margin around full thickness of pinna
- 5cm circle applicator
- 150 kV photons
- HVL 6mm Al
- Shield behind ear
- Bolus*
- 50 Gy / 20

Case 2 – BCC of Nasal Ala



- 0.7cm margin around full thickness of pinna
- 3cmcm circle applicator
- 150 kV photons
- HVL 6mm Al
- 50 Gy / 20
- Shield in left nostril to protect nasal septum
- Consider shield in upper gum

Dose Distributions



Radiation Oncology Physics: A Handbook for Teachers and Students – 8.1.1

Electron PDD



Field size effect on electron PDD




Incident electron
Absorber
(b)
Electron absorbed



Electron Cutouts - Standard

- Available in a variety of sizes
- Applicators range from 10 cm x 10 cm up to 25 cm x 25 cm in size

Skin Brachytherapy

- Common approaches
  - Surface moulds
  - Electronic brachytherapy approaches
    - Valencia and Leipzig applicators
  - Freiburg Flap applicator
- Electronic brachytherapy becoming more common in USA, especially in dermatology practices as energies required do not need MV or active source radiation license

Freiburg flap applicator



J. Park et al, JACMP 2014

Surface Moulds

Clinical Investigations

Original paper

High-dose-rate skin brachytherapy with interstitial, surface, or a combination of interstitial and surface mold technique

Serhii Brovchuk, PhD[1], Sang-June Park, PhD[2], Zoia Shepil, MD[1], Serhii Romanenko, MD[1], Oleg Vaskevych, MD[1]

[1]Radiotherapy Department, Kyiv Regional Oncology Dispensary, Kyiv, Ukraine, [2]Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA

Fig. 1



A 62-year-old patient with basal cell carcinoma (BCC), superficial treatment. **A, B**) On first day of treatment

Valencia Applicator



- Has a flattening filter
  - Slower dose rate
  - Flatter edges
- 3cm applicator for a 2.5cm lesion

Leipzig applicator



- No flattening filter, faster
- Less uniform isodose, larger ‘penumbra’
- 3cm diameter for 2cm lesion

Interstitial skin brachytherapy

- Excellent for conformal treatment for thicker lesions, face, more suitable for hypofractionated/accelerated treatment
- Excellent OAR sparing, especially near orbit
- Depending on bulk, may need surface mould, more than a single plane of applicators if >5mm depth

Interstitial Skin Brachytherapy



Fig. 5. A 63-year-old patient with BCC, interstitial treatment of two localizations. **A**, **B**) First day of treatment, **C**, **D**) six's day of treatment, and **E**, **F**) three months after BT

Overlap between surface brachytherapy and orthovoltage cases



Fig. 2. An example of an 82-year-old female patient, who presented with a lesion of the medial inferior eyelid (**A**). Flap
plicator was placed, and thermoplastic mask was created to secure its position (**B**). Simulation CT was obtained (**C**). 40 G
8 twice weekly fractions was delivered using HDR-brachytherapy. During the final week of treatment, she developed gra
onjunctivitis, which was treated with a two-day course of antibiotic/steroid eye suspension. On initial follow-up one-mo
st-treatment, her conjunctivitis had resolved, and the lesion had diminished in size. By follow-up at seven months, her le
completely resolved, with minimal hypopigmentation or scarring (**D**)

Anatomy – Dunn, British Journal of Plastic Surgery 1997



Fig. 1

Key to Figures 1–2

Key code	*Commonest name*		*Alternative name*	*Second alternative*
F	1	hairline		
F	2	upper forehead crease	frontalis-galea edge	
F	3	forehead creases	forehead lines	frown line
F	4	forehead		
F	5	eyebrow		
F	6	supra-orbital margin		
F	7	naso-labial crease	naso-labial groove	naso-labial fold
F	8	buccal pit	buccal fovea	
F	9	bucco mandibular groove		
F	10	marionette line	down line	oromental crease
F	11	mental crease	labio-mental crease	mentolabial groove
F	12	mental pit		
F	13	median chin crease	chin crease/cleft	mental crease/groove
F	14	chin		
F	15	sideburn		
F	16	vertical glabellar lines		
F	17	glabella		
F	18	external nose		
F	19	transverse nasal grooves		
F	20	nasal root		
F	21	nasal bridge		
F	22	chin-neck angle	cervico-submental angle	cervico-mental angle
F	23	vertical ramus of mandible	ascending ramus of mandible	
F	24	angle of mandible		
F	25	horizontal ramus of mandible	jawline	
F	26	nape of neck		



Fig. 3

Figure 3—Eye (key code Y).

Key to Figure 3

	Key code	*Commonest name*		*Alternative name*	*Second alternative*
	Y	1	plica semilunaris		
	Y	2	lacrimal caruncle		
	Y	3	medial canthus		
	Y	4	lateral canthus	outer canthus	
	Y	5	grey margin		
	Y	6	lash margin	ciliary margin	
	Y	7	palpebral fissure		
	Y	8	pupil		
	Y	9	iris		
	Y	10	cornea		
	Y	11	limbus		
	Y	12	sclera		
	Y	13	upper eyelid		
	Y	14	upper lid crease	superior palpebral fold	superior tarsal fold
	Y	15	lower eyelid		
*	Y	16	lower lid crease	inferior palpebral fold	inferior tarsal fold
*	Y	17	infra orbital crease	infra orbital margin	
*	Y	18	lateral canthal creases	eyelid creases	crowsfeet/plica

*Denotes the feature is repeated on Figure 2.



Fig. 4

Figure 4—Nose and mouth (key codes N+F).

Key to Figure 4

	Key code	*Commonest name*		*Alternative name*	*Second alternative*
	N	1	upper lip		
	N	2	lower lip		
*	N	3	columella-lip angle		
	N	4	oral fissure	oral aperture	
	N	5	commissure	angle of mouth	
	N	6	commissural crease		
	N	7	philtrum	philtral groove	philtral dimple
	N	8	philtral column	philtral pillar	philtral ridge
	N	9	cupid's bow		
	N	10	circumoral site	rhytides	
	N	11	white roll		
	N	12	lip tubercle	tubercle of upper lip	
	N	13	vermilion border	vermilion-cutaneous border	
	N	14	dry vermilion	vermilion	
	N	15	wet vermillion	wet/dry border	inner vermilion
*	N	16	supra tip		
	N	17	nose tip	nose apex	
	N	18	nose tip groove		
*	N	19	columella		
*	N	20	naso-facial sulcus	para-nasal sulcus	
*	N	21	naso-alar sulcus		
	N	22	naso-labial-alar angle		
*	N	23	alar crease		
	N	24	ala		
	N	25	nostril margin	alar margin	
	N	26	nostril sill		
	N	27	nostril	nares	
	N	28	soft triangle		

*Denotes the feature is repeated on Figure 2.



Fig. 5

Figure 5—Ear (key code E).

Key to Figure 5

	Key code	*Commonest name*		*Alternative name*	*Second alternative*
*	E	1	pre-auricular sulcus	pre-tragal sulcus	
	E	2	anterior notch	anterior incisura	
	E	3	supratragal tubercle	supratragal tuberculum	
	E	4	tragus		
	E	5	intertragal notch	intertragal incisura	incisura
	E	6	antitragus	antetragus	
	E	7	lobe	lobule	
*	E	8	posterior auricular sulcus	posterior auricular groove	
*	E	9	pinna	auricle	external ear
	E	10	helix		
	E	11	helical rim	rim	
	E	12	helical margin		
	E	13	Darwin's tubercle	auricular tubercle	
	E	14	scaphoid fossa	scapha fossa	
	E	15	antihelix	antehelix	
	E	16	upper crus of antihelix	superior crus of antihelix	
	E	17	triangular fossa		
	E	18	lower crus of antihelix	inferior crus of antihelix	
	E	19	cymba conchae		
	E	20	crus of helix	root of helix	
	E	21	conchal fossa		
	E	22	conchal cave	cavum conchae	
	E	23	external meatus		
	E	24	terminal notch		

*Denotes the feature is repeated on Figure 2.



Good luck everyone

jordan.stosky@ahs.ca